Corporate Information
CEO Message
Mission
Corporate Information
Corporate Governance
Business
Stemrim History
About “Regeneration-Inducing Medicine
™
”
What is “Regeneration-Inducing Medicine
™
”?
Issues of Conventional Cell Therapy
The Superiority of “Regeneration-Inducing Medicine
™
”
Business
Areas of Disease and Pipeline
“Regeneration-Inducing Medicine
™
”
Autologous cell sampling devices for medical treatment
Stem cells gene therapy
Research Paper
Investor Relations
COO Message
Investor News
ESG
Financial Data
Investor Library
Investor Calendar
Analyst Coverage
Stock Prices
Investor Relations
Timely Disclosure Information
January 15, 2025
StemRIM Announces the Extension of the Term for the Tripartite Joint Research Agreement Aimed at Elucidating Skin Anti-Aging Mechanisms
December 23, 2024
StemRIM Announces the First Administration of Phase 2 Clinical Trial for Redasemtide Targeting Ischemic Cardiomyopathy
December 12, 2024
[Delayed]StemRIM Announces Selection for the AMED Project “FY2024 Project for Fundamental Technology Development toward Industrialization of Regenerative Medicine and Gene Therapy”
December 11, 2024
StemRIM Announces Completion of Payment for Issuance of New Shares as Restricted Stock Compensation
December 09, 2024
StemRIM Announces Patent Registration (Europe) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Chronic Heart Failure Caused Thereby
Click here for past list
StemRIM
>
Investor Relations
>
Investor Library
>
Timely Disclosure Information
